Janugliflozin 25 mg Tablet (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Youngpoong Pharmaceutical Co., Ltd.
MFDS item code 202004038 · Approved 2020.05.29
This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone to newly diagnosed patients receiving initial diabetes medication treatment, and if monotherapy does not adequately control blood sugar levels, it can be used in combination with metformin. Furthermore, it is administered in combination when blood sugar control is difficult with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin. Therefore, this medication plays an important role in improving blood sugar control at various stages of treatment.
This medicine is administered at 100 mg once daily as monotherapy or in combination therapy, with a maximum daily dose of 100 mg. It may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Since dose adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. The dose for patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2) is 50 mg once daily. 4. The dose for patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2) is 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.
This medicine can rarely cause severe allergic reactions; therefore, if symptoms such as skin rash or difficulty breathing occur, its use should be stopped immediately and medical consultation sought. Additionally, acute pancreatitis, which involves inflammation of the pancreas, may occur, so if abdominal pain, vomiting, or severe abdominal discomfort is felt, immediate medical attention is necessary. This drug should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in patients allergic to any of the drug components. Patients with reduced kidney function may experience a slower excretion of the medication, requiring dose adjustments or cautious use, along with regular kidney function tests. When used with other diabetes medications or insulin that can cause hypoglycemia, close attention to hypoglycemic symptoms is advised, and dose adjustments of other medications may be necessary. During the use of this drug, symptoms such as headache, upper respiratory infection, pharyngitis, diarrhea, and nausea may occur, and if they are severe or persistent, medical consultation should be sought. The safety of this drug has not been established in pregnant or nursing women, and its use is not recommended in children or adolescents under 18 years of age. In the elderly, dose adjustments and kidney function monitoring are necessary as kidney function may decline. In case of overdose, immediate medical attention is necessary to receive appropriate treatment, and some medications can be removed via hemodialysis. This drug has relatively few interactions with other medications, but caution is required when taking certain medications, thus it is important to inform healthcare providers about all medications being taken. If severe joint pain or skin blistering occurs during treatment, discontinue the drug and seek evaluation from a specialist.
Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative skin disease, acute pancreatitis, hypoglycemia, upper respiratory infections, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, constipation, vomiting, severe joint pain accompanied by disability, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased blood triglycerides, gastritis, severe hypoglycemia
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and it is best to keep it at room temperature between 1°C and 30°C. Proper storage will help maintain the drug's effectiveness for a longer period.
Light orange, round, biconvex, film-coated tablet
28 tablets/PtP [14 tablets/PtP * 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Youngpoong Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.